Comparison of Utilization and Clinical Outcomes for Belatacept- and Tacrolimus- Based Immunosuppression in Renal Transplant Recipients (original) (raw)

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2016

Abstract

The performance of belatacept in a real clinical setting has not been reported. A retrospective cohort study was conducted using registry data comparing one-year clinical outcomes between belatacept- and tacrolimus-treated adult kidney transplant recipients (KTR) from 6.1.2011 through 12.1.2014. Of 50 244 total patients, 417 received belatacept+tacrolimus, 458 received belatacept alone, and 49 369 received tacrolimus alone at discharge. In the overall study cohort, belatacept alone was associated with a higher risk for one-year acute rejection, with highest rates associated with non-lymphocyte depleting (LD) induction (aHR: 2.65; 95%CI: 1.90-3.70, P<.0001). There was no significant difference in rejection rates between belatacept+tacrolimus and tacrolimus alone. In KTR meeting inclusion criteria for the BENEFIT-EXT trial, one-year kidney function was higher with belatacept+tacrolimus and belatacept alone versus tacrolimus alone groups (mean eGFR: 65.6 vs 60.4 vs 54.3 ml/min/1.73M...

Xuerong Wen hasn't uploaded this paper.

Let Xuerong know you want this paper to be uploaded.

Ask for this paper to be uploaded.